Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Cash from Operations: 2022-2023

Historic Cash from Operations for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to -$14.0 million.

  • Lexeo Therapeutics' Cash from Operations rose 15.91% to -$14.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$59.5 million, marking a year-over-year change of. This contributed to the annual value of -$81.2 million for FY2024, which is 36.40% down from last year.
  • Lexeo Therapeutics' Cash from Operations amounted to -$14.0 million in Q4 2023, which was down 0.23% from -$13.9 million recorded in Q3 2023.
  • Lexeo Therapeutics' 5-year Cash from Operations high stood at -$13.2 million for Q2 2023, and its period low was -$18.4 million during Q1 2023.
  • Its 2-year average for Cash from Operations is -$15.2 million, with a median of -$14.0 million in 2023.
  • Data for Lexeo Therapeutics' Cash from Operations shows a peak YoY increased of 15.91% (in 2023) over the last 5 years.
  • Lexeo Therapeutics' Cash from Operations (Quarterly) stood at -$16.6 million in 2022, then climbed by 15.91% to -$14.0 million in 2023.
  • Its last three reported values are -$14.0 million in Q4 2023, -$13.9 million for Q3 2023, and -$13.2 million during Q2 2023.